Centaurus Financial’s CytomX Therapeutics CTMX Stock Holding History

Centaurus Financial’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-400	Closed	-$9K	–	832
2018 Q2	$9K	Buy	+400	New	+$10.2K	﹤0.01%	1585

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Centaurus Financial's CTMX Position: Q3 2018 in Review

Centaurus Financial sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 400 shares — an estimated $9K sold.

Centaurus Financial first reported a position in CTMX in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

Centaurus Financial reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 400 CytomX Therapeutics shares in Q3 2018, an estimated $9K.
Centaurus Financial first reported a position in CytomX Therapeutics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's CytomX Therapeutics position peaked at $9K in Q2 2018.
122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.